Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.


Lu S., Ahn M., Reungwetwattana T., Özgüroğlu M., Kato T., Yang J. C., ...Daha Fazla

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 (SCI-Expanded, Scopus) identifier